Stay updated with breaking news from Polymerase Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
Proceeds will be used to advance clinical program of GNSC-001, company's lead candidate in osteoarthritis (OA) Brian Kotzin, M.D., and Jackson Streeter, M.D.,...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Share this article PALO ALTO, Calif., May 5, 2021 /PRNewswire/ -- Â Genascence Corporation, a clinical-stage biotechnology company developing life-changing gene therapy products for prevalent musculoskeletal diseases, today announced that dosing across all three cohorts has been completed in the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA). GNSC-001 is an adeno-associated vector (AAV) carrying a coding sequence for interleukin-1 receptor antagonist (IL-1Ra), a potent inhibitor of interleukin-1 (IL-1) signaling. IL-1 is considered one of the key mediators involve...